Laser Attraction
Early experience with dermatologic laser treatments set Edward Glassberg, MD, on the path to becoming cofounder of the 13,000-square-foot Laser Skin Care Center.

As a teenager, Edward Glassberg, MD, struggled with severe acne and was treated by a dermatologist for several years. The experience led him to consider a career in medicine. After graduating summa cum laude from the University of California, Los Angeles with a Bachelors of Science degree, he was accepted into the University of Southern California (USC) School of Medicine.

“I considered going...

Articles

Laser Attraction

As a teenager, Edward Glassberg, MD, struggled with severe acne and was treated by a...

Fillers for midface rejuvenation

The middle third of the face extends from the infraorbital rim to the upper lip and...

Identify and eliminate slow-selling procedures and products

As any good gardener knows, in order to have a healthy tree that bears plentiful,...

The pros and cons of private label skin care.

Retail skincare products offer several benefits to aesthetic patients and practices....

Products

Noninvasive fat reduction for arms

The CoolAdvantage Petite applicator from Zeltiq is designed to deliver...

Broad spectrum sun protection

Eau Thermale Avène Hydrating Sunscreen Balm SPF 50+ provides broad spectrum...

Hydrating oil for dry skin

Pharmagel Nourish Oil blends 12 natural oils with vitamins C and E to...

Hyaluronic acid-based skin care

The Hyla3D HA Activating Complex from Jan Marini Skin Research is formulated...

Blogs

Facebook Ad Leads
By Angela (Miller) Hamilton, Facebook Marketing Expert at ReachLocal With more than 1.71 billion active users on Facebook, social media advertising is an important way for medspas and medical practices to reach local consumers online. Most facilties have a company page and perhaps purchase a few...
Addressing Employee Tardiness
By Paul Edwards, CEO of CEDR HR Solutions There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away. Despite the many...
RepliCel Dermal Injection Technologies Receive U.S. Patent

RepliCel Life Sciences has been granted a U.S. patent (No. 9,616,182) covering significant components of its novel, multi-needle dermal injection device. The patent relates to technologies designed to enable better control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.

The first device being developed under this patent, RCI-02, is designed to inject soft tissue fillers such as hyaluronic acid. The device is also being developed for the injection of RepliCel's RCH-01 hair restoration and RCS-01 skin rejuvenation products. Future iterations of the device will be optimized for other injectables such as drugs, biologics, vaccines and fat grafts.

RCI-02 is a motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetizing and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or...

Comparing Procedure Pricing

When reviewing your procedure pricing, it can be helpful to know what other practitioners are charging for similar treatments. If you see that your prices are significantly higher—or lower—than national averages, it may be a sign that it’s time to adjust your fees.

As part of its 2016 survey on medical cosmetic treatments, the American Society of Plastic Surgeons (ASPS) asked physicians to share not only how many procedures they had performed, but also what they charge. Below are the national average costs for some of the most popular surgical and nonsurgical aesthetic services.

Surgical procedures:

  • Breast Augmentation: national average cost of $3,719
  • Liposuction: national average cost of $3,200
  • Rhinoplasty: national average cost of $5,046
  • Abdominoplasty: national average cost of $5,798
  • Buttock Augmentation: national average cost of $4,356

Nonsurgical procedures:

  • Botulinum toxin injections: national average cost of $385
  • Soft tissue fillers (hyaluronic acid): national average cost of $644
  • Chemical peels: national average cost of $673
  • Microdermabrasion: national average cost of $138
  • Intesne pulsed light (IPL...
Taro Pharmaceuticals to Distribute Pliaglis in the U.S.

Crescita Therapeutics has granted Taro Pharmaceuticals an exclusive license to the rights to sell and distribute Pliaglis, a topical anesthetic that sets into a peelable mask, in the U.S. market. The license agreement also includes a second-generation, patent-ending enhanced version of Pliaglis. Crescita will retain all rights to the product in Canada and Mexico.

Pliaglis is a topical local anesthetic ( lidocaine 7%/tetracaine 7%) that can be used prior to superficial aesthetic treatments, such as injectables and laser procedures. The product features a proprietary phase-changing topical cream “Peel” technology, which consists of a drug-containing cream that, once applied to a patient's skin, dries to form a pliable layer that releases drug into the skin. Following the application period, Pliaglis is removed from the skin allowing the dermatological procedure to be performed with minimal to no pain.

“We are delighted to have Taro as our new licensing partner for Pliaglis in the U.S.,” said Dan Chicoine, executive chairman and interim CEO of Crescita. “Taro is a leading supplier of topical dermatological products in the U.S. We look forward to working with Taro to not only reintroduce Pliaglis to the U.S. market...

Biologic Therapy Dupixent (Dupilumab) Approved For Atopic Dermatitis

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) Injection from Regeneron Pharmaceuticals, and Sanofi for the treatment of adults with moderate-to-severe atopic dermatitis (AD).


Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. It comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose and can be used... more »

AAD Commends FDA for Indoor Tanning Restrictions

The American Academy of Dermatology (AAD) applauds the U.S. Food and Drug Administration (FDA) for proposing new regulations governing indoor tanning, including an age restriction for minors under the age of 18 as well as a risk-acknowledgement form that all adults must sign before using indoor tanning devices.


According to the AAD, statistics show that millions of people tan indoors annually and the risk of developing melanoma increases by 59% for individuals exposed to UV radiation from indoor tanning—the risk increases with each use. If the FDA’s proposed rule becomes final,... more »

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.


The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.


The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »